Concord Biotech growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	−12.1%	—
EBITDA	−27.5%	—
Net Income	−30.3%	—
EPS (adj.)	−29.8%	—
Total Assets	+9.9%	—
Total Equity	+11.2%	—
Free Cash Flow	+28.8%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health

₹ CrorePeersBIOCON DIVISLAB CAPLIPOINT EMCURE BLUEJET ERIS GRANULES ACUTAASMcap ₹12,874 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	-12.1	—
EBITDA	-27.5	—
Net Income	-30.3	—
EPS (adj.)	-29.8	—
Total Assets	+9.9	—
Total Equity	+11.2	—
Free Cash Flow	+28.8	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.